Related Experiment Video

Updated: Aug 5, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K

Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?

Irina Gîrleanu1,2, Anca Trifan1,2, Laura Huiban1,2

  • 1Department of Gastroenterology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

Diagnostics (Basel, Switzerland)
|March 29, 2023
PubMed

Insights

Anticoagulant therapy for atrial fibrillation in liver cirrhosis is debated due to bleeding risks. However, recent data suggest direct oral anticoagulants may be safe in compensated cirrhosis, but contraindicated in severe cases.

Area of Science:

  • Cardiology
  • Hepatology
  • Pharmacology

Background:

  • Atrial fibrillation is common in liver cirrhosis, particularly with non-alcoholic steatohepatitis or alcoholic causes.
  • Anticoagulation is standard for thromboembolic prevention in atrial fibrillation but complex in cirrhosis due to altered coagulation.
  • Previous trials excluded cirrhotic patients, creating uncertainty about anticoagulant safety and efficacy.

Purpose of the Study:

  • To review current evidence on the safety and efficacy of anticoagulant treatment in patients with decompensated liver cirrhosis.
  • To evaluate the role of direct oral anticoagulants versus warfarin in this population.
  • To identify needs for improved risk stratification and personalized treatment.

Main Methods:

  • Systematic review of recent real-life cohort data.
  • Analysis of safety and efficacy outcomes of anticoagulation in liver cirrhosis.
  • Comparison of direct oral anticoagulants and warfarin.

Main Results:

  • Real-world data indicate anticoagulant treatment can be safe in liver cirrhosis patients.
  • Direct oral anticoagulants demonstrate better safety profiles than warfarin in compensated liver cirrhosis.
  • Direct oral anticoagulants are contraindicated in Child-Pugh class C liver cirrhosis.

Conclusions:

  • Anticoagulant therapy in liver cirrhosis requires careful consideration of disease severity.
  • Development of specific risk scores and bleeding biomarkers is crucial for personalized anticoagulation.
  • Further research is needed to optimize treatment strategies for this complex patient group.

Keywords:
anticoagulationatrial fibrillationbleedingliver cirrhosisrisk factorsstroke

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

596

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
13
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
792
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
18
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
108
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K